APYX

Apyx Medical Corporation

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Apyx Medical Corporation (APYX) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (C-). The rating has held at C+ for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C-
Factor Score 2.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -13.9
EV / EBITDA -51.0
Rev Growth YoY 9.0%
Gross Margin 63.4%
Price Return 3M -14.8%
Price Return 12M -34.9%
Catalyst Signal 0.00
Market Cap $111.6M
TTM Revenue $59.6M
Price / Sales 1.9
ROE -102.5%

Historical Factor Score Progression

Held C+ for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) C- (2.1) C+ (2.8) C- (2.1) C+ (2.6) C+ (2.5)
2026-11-10 B- (3.0) C- (2.0) B- (2.9) C (2.3) C+ (2.6) C+ (2.6)
2026-11-03 B- (3.0) C (2.2) B- (2.9) C- (1.9) C+ (2.7) C+ (2.5)
2026-10-27 B- (3.0) C (2.2) B- (2.9) D+ (1.8) C+ (2.6) C+ (2.5)
2026-10-20 B- (3.0) C (2.2) B- (2.9) D+ (1.7) C+ (2.6) C (2.5)
Page 1 of 8
…